A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma

Latest Drug Updates

Patients eligible for transplant,Patients non-eligible for transplant,Relapsed/refractory patients

Galinpepimut-S granted FDA orphan drug designation

May 11, 2018
Patients eligible for transplant,Patients non-eligible for transplant

Daratumumab approved by FDA for frontline use

May 8, 2018
Relapsed/refractory patients

Selinexor receives FDA fast track designation 

Apr 13, 2018

Where we are next

23rd Congress of the European Hematology Association (EHA)

June 14–17, 2018 | Stockholm, SE

The MM Hub will be attending the 23rd Congress of the European Hematology Association (EHA) to be held in Stockholm, Sweden, in June at the Stockholmsmässan conference center. The meeting prides itself on bringing together professionals worldwide to highlight 'state-of-the-art clinical practice and the latest findings in hematology research'. There will also be specialist satellite sessions and an exhibition hall. The program covers all hematological indications, including Multiple Myeloma (MM). Stay tuned to the MM Hub to follow our first-hand coverage.

#EHA23 #mmsm 

Event Website

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology